Sign In
Last checked at 
14 Dec 2020 07:00
LEI: 549300Q7EXQQH6KF7Z84
14 December 2020
RTW Venture Fund Limited
Net Asset Value
RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 30 November 2020 (the "NAV") was US$308.3 million, or US$1.61 per ordinary share.
As at 30 November 2020, 25.7 per cent. of the total NAV was invested in privately-held core portfolio companies.
To note, given positive news on clinical trials progress of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), the largest holding in the Company's portfolio, Rocket's share price traded up +83% on 09 December 2020, translating into a materially accretive NAV performance for the Company. This event will be reflected in the Company's December NAV.
For Further Information
RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Business Development Associate
Ocorian (Company Secretary) +44 (0)1481 742 642Kevin Smith
J.P. Morgan Cazenove +44 (0)20 7742 4000
William Simmonds
Jérémie Birnbaum
James Bouverat (Sales)
Barclays +44 (0)20 7623 2323
Tom Swerling
Andrew Tusa
Note:
1. | The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 30 November 2020. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions. |
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Follow the stocks
